Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho
May 19, 2021 12:42 PM EDTMizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.
"The commercial potential for lifileucel remains but the question... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA Push
May 19, 2021 8:05 AM EDTStifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a Buy rating.
The analyst commented, "Although yesterday's update has us scratching our heads and leaves us with a number of outstanding questions, we remain... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay
May 19, 2021 7:58 AM EDTChardan Capital Markets analyst Geulah Livshits lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $51.00 (from $54.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, after market close, Iovance Biotherapeutics announced revised guidance for BLA filing on tumor infiltrating lymphocyte (TIL)... More
